Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Nyxoah S.A.NASDAQ: NYXH
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of €7.36M rose 591.9% year over year, ahead of the +273.9% change in trailing-twelve-month revenue. Sequentially, it rose 30.4% from the prior quarter. Over 3 fiscal years it compounded at +48.1% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of €37.32M (+272.5%) for the fiscal year ending Dec 2026, a step up from the +121.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- €7.36M+30.4% QoQ
- Last fiscal yearDec 2025
- €10.02M+121.6% YoY
- LTMMar 2026
- €16.32M+273.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +591.9% | +544.5% | -47.4 pp |
| 1 year | +121.6% | +272.5% | +150.8 pp |
| 3-year CAGR | +48.1% | +124.3% | +76.2 pp |
| 5-year CAGR | +93.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
EUR · from the income statement
- Latest · FY2025
- 10.02M EUR
- Year-over-year change
- +121.6%
- 4-year CAGR
- +85.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.02M | +121.6% |
| FY2024 | 2024-12-31 | 4.52M | +4.0% |
| FY2023 | 2023-12-31 | 4.35M | +41.0% |
| FY2022 | 2022-12-31 | 3.08M | +262.0% |
| FY2021 | 2021-12-31 | 852K | — |
Revenue vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +273.9% is the highest of 9, against a peer median of +15.7%.
- Over three fiscal years its annual growth of +48.1% compares with a peer median of -9.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $151.64M USD | +69.5% | +31.8% | |
| LTM Mar 2026 | $113.75M USD | +174.0% | +91.5% | |
| LTM Mar 2026 | $113.02M USD | -30.1% | -33.3% | |
| LTM Mar 2026 | $55.87M USD | +52.3% | — | |
| LTM Mar 2026 | $43.26M USD | +23.3% | +13.8% | |
| LTM Mar 2026 | $37.53M USD | -4.4% | -9.7% | |
| LTM Mar 2026 | $28.91M USD | +8.1% | -31.9% | |
| LTM Mar 2026 | €16.32M EUR | +273.9% | +48.1% | |
| LTM Mar 2026 | $618K USD | -58.0% | -50.1% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding NYXH) | — | +15.7% | -9.7% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 852K | 3.08M | 4.35M | 4.52M | 10.02M |
| Cost of Revenue | 303K | 1.15M | 1.66M | 1.55M | 3.69M |
| Gross Profit | 549K | 1.93M | 2.69M | 2.97M | 6.33M |
| Gross Margin | 64.4% | 62.7% | 61.9% | 65.7% | 63.1% |
| Research & Development | 5.95M | 15.86M | 27.66M | 34.33M | 42.82M |
| Selling, General & Admin | 11.11M | 18.86M | 20.65M | 28.46M | 46.44M |
| Operating Expenses | 26.79M | 34.43M | 47.79M | 61.78M | 89.27M |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 764K | 4.48M |
| EBITDA | (22.59M) | (27.89M) | (42.08M) | (53.77M) | (82.9M) |
| EBITDA Margin | -2651.5% | -904.2% | -967.8% | -1189.2% | -827.4% |
| Operating Income | (26.24M) | (32.5M) | (45.1M) | (58.81M) | (82.94M) |
| Operating Margin | -3080.0% | -1053.8% | -1037.3% | -1300.8% | -827.8% |
| Interest Income | 1K | 372K | 2.57M | 2.5M | 1.83M |
| Interest Expense | 386K | 237K | 1.21M | 1.9M | 1.69M |
| Other Income / Expenses | 1.6M | 2.44M | 445K | 2.38M | (6.13M) |
| Income Before Tax | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (89.08M) |
| Pre-Tax Margin | -2891.9% | -974.6% | -1027.1% | -1248.2% | -889.0% |
| Income Tax Expense | 2.98M | 1.17M | (1.45M) | 2.8M | 1.01M |
| Net Income | (27.62M) | (31.23M) | (43.21M) | (59.24M) | (90.09M) |
| Net Margin | -3241.7% | -1012.5% | -993.8% | -1310.2% | -899.1% |
| EPS (Basic) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| EPS (Diluted) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| Weighted Avg Shares | 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
| Weighted Avg Shares (Diluted) | 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.